Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma

By LabMedica International staff writers
Posted on 24 Apr 2026

Many patients with advanced melanoma start on anti-PD-1 immunotherapy, but responses can wane or never develop. More...

Clinicians often turn to anti-CTLA-4 after resistance emerges, yet predicting who will respond remains difficult. Understanding how immune cells behave within the tumor microenvironment may explain persistent resistance despite combination treatment. New findings demonstrate that the spatial organization of immune cells inside tumors may indicate which patients benefit from combination immunotherapy after anti-PD-1 failure.

A new study  from UCLA Health Jonsson Comprehensive Cancer Center (Los Angeles, CA, USA) identifies “cellular neighborhoods”—organized patterns of interaction among immune and melanoma cells—as potential indicators of response to ipilimumab plus nivolumab after anti-PD-1 therapy has stopped working. The analysis found that intratumoral immune architecture, rather than tumor genetics alone, distinguished responders from non-responders. Tumors with active networks of cancer‑killing T cells were linked to clinical benefit, while tumors dominated by dense plasma cell clusters were far less likely to benefit.

Researchers analyzed tumor biopsies from patients enrolled in the SWOG S1616 clinical trial, all with melanoma that had progressed on anti-PD-1 therapy. Participants were randomized to receive ipilimumab (targets CTLA-4) plus nivolumab (targets PD-1) or ipilimumab alone, with biopsies obtained before treatment and again about one month later. Working with collaborators at the Parker Institute for Cancer Immunotherapy and industry partners, the team combined genetic sequencing with high‑resolution imaging to map which genes were active and where immune and cancer cells were physically located within each tumor.

Responders to combination therapy showed CD8 T cells entering tumors and clustering tightly around melanoma cells, alongside evidence of active immune signaling and dividing CD8 populations near tumor cells. As tumors began to shrink, additional immune cells, including regulatory T cells and monocytes, appeared in the microenvironment, forming coordinated cellular neighborhoods. Non‑responding tumors frequently contained plasma cell–rich regions associated with reduced T‑cell activity and continued growth. In responding tumors, T cells were positioned near blood vessels and supportive immune cells, facilitating infiltration and coordinated attack.

The study is published in Cancer Discovery. The findings suggest tumor structure—not just genetics—may help guide treatment selection in melanoma, identifying patients most likely to benefit from combination immunotherapy and those who may need a different approach sooner. Next steps cited by the researchers include learning how to reshape resistant tumor environments and how best to combine immunotherapy with targeted therapy, chemotherapy, or radiation.

“The T cells need to directly see the cancer cells to kill them, but they also need to be able to move around and get the correct signals to tell them to keep going or keep killing,” said Dr. Katie Campbell, adjunct assistant professor of medicine at the David Geffen School of Medicine at UCLA and first author of the study. "If they can't get into the tumor through blood vessels, or don't get these signals because the right types of immune cells aren't there, the patient isn't going to respond to the therapy."

Related Links
UCLA Health Jonsson Comprehensive Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.